tbuckley/cabot-search huggingface dataset:
Can vestibular rehabilitation exercises help patients with concussion? A systematic review of efficacy, prescription and progression patterns
Authors: Drew A Murray, Dara Meldrum, Olive Lennon
Journal: British Journal of Sports Medicine (2016)

Objective Concussion symptoms normally resolve within 7–10 days but vertigo, dizziness and balance dysfunction persist in 10–30% of cases causing significant morbidity. This study systematically evaluated the evidence supporting the efficacy, prescription and progression patterns of vestibular rehabilitation therapy (VRT) in patients with concussion. Design Systematic Review, guided by PRISMA guidelines and presenting a best evidence synthesis. Data sources Electronic databases PubMed (1949 to May 2015), CINAHL (1982 to May 2015), EMBASE (1947 to May 2015), SPORTDiscus (1985 to May 2015), Web of Science (1945 to May 2015) and PEDRO (1999 to May 2015), supplemented by manual searches and grey literature. Eligibility criteria for study selection Article or abstract of original research, population of patients with concussion/mild traumatic brain injury (mTBI) with vestibular symptoms, interventions detailing VRT, measurement of outcomes pre-VRT/post-VRT. Study type was not specified. Results Following a double review of abstract and full-text articles, 10 studies met the inclusion criteria: randomised controlled trial (n=2), uncontrolled studies (n=3) and case studies (n=5). 4 studies evaluated VRT as a single intervention. 6 studies incorporated VRT in multimodal interventions (including manual therapy, strength training, occupational tasks, counselling or medication). 9 studies reported improvement in outcomes but level I evidence from only 1 study was found that demonstrated increased rates (OR 3.91; 95% CI 1.34 to 11.34; p=0.002) of medical clearance for return to sport within 8 weeks, when VRT (combined with cervical therapy) was compared with usual care. Heterogeneity in study type and outcomes precluded meta-analysis. Habituation and adaptation exercises were employed in 8 studies and balance exercises in 9 studies. Prescription and progression patterns lacked standardisation. Conclusions Current evidence for optimal prescription and efficacy of VRT in patients with mTBI/concussion is limited. Available evidence, although weak, shows promise in this population. Further high-level studies evaluating the effects of VRT in patients with mTBI/concussion with vestibular and/or balance dysfunction are required.
Risk for Congenital Malformation With H1N1 Influenza Vaccine
Authors: Jonas F. Ludvigsson, Peter Ström, Cecilia Lundholm, Sven Cnattingius, Anders Ekbom, Åke Örtqvist, Nils Feltelius, Fredrik Granath, Olof Stephansson
Journal: Annals of Internal Medicine (2016)

Background: Earlier studies reporting varying risk estimates for congenital malformation in offspring of mothers undergoing vaccination against H1N1 influenza during pregnancy did not consider the potential role of confounding by familial (genetic and shared environmental) factors. Objective: To evaluate an association between maternal H1N1 vaccination during pregnancy and offspring malformation, with familial factors taken into account. Design: Population-based prospective study. Setting: Sweden. Participants: Liveborn offspring born between 1 October 2009 and 1 October 2011 to mothers receiving monovalent AS03-adjuvanted H1N1 influenza vaccine (Pandemrix [GlaxoSmithKline]) during pregnancy. A total of 40 983 offspring were prenatally exposed to the vaccine, 14 385 were exposed within the first trimester (14 weeks), and 7502 were exposed during the first 8 weeks of pregnancy. Exposed offspring were compared with 197 588 unexposed offspring. Corresponding risks in exposed versus unexposed siblings were also estimated. Measurements: Congenital malformation, with subanalyses for congenital heart disease, oral cleft, and limb deficiency. Results: Congenital malformation was observed in 2037 (4.97%) exposed offspring and 9443 (4.78%) unexposed offspring. Adjusted risk for congenital malformation was 4.98% in exposed offspring versus 4.96% in unexposed offspring (risk difference, 0.02% [95% CI, −0.26% to 0.30%]). The corresponding risk differences were 0.16% (CI, −0.23% to 0.56%) for vaccination during the first trimester and 0.10% (CI, −0.41% to 0.62%) for vaccination in the first 8 weeks. Using siblings as comparators yielded no statistically significant risk differences. Limitations: The study was based on live births, and the possibility that data on miscarriage or induced abortion could have influenced the findings cannot be ruled out. Study power was limited in analyses of specific malformations. Conclusion: When intrafamilial factors were taken into consideration, H1N1 vaccination during pregnancy did not seem to be linked to overall congenital malformation in offspring, although risk increases for specific malformations could not be ruled out completely. Primary Funding Source: Swedish Research Council and Swedish Council for Working Life and Social Research.
Modulation of the Non-Canonical NFKB Pathways may Underlie Alternative Activation of Circulating CD14HI Monocytes in Hyper-Acute Liver Failure
Authors: R.D. Abeles, C. Antoniades, G. Manakkat-Vijay, D. Shawcross, W. Khamri, N. Vergis, W. Bernal, J. Wendon, D. Vergani
Journal: Journal of Hepatology (2016)
A New Model for Studying Interaction between Hepatitis B Virus and Host Cells Derived from Human Induced Pluripotent Stem Cells
Authors: S. Kaneko, S. Kakinuma, Y. Asahina, A. Kamiya, S. Nitta, T. Tsunoda, M. Miyoshi, Y. Asano, H. Nagata, F. Goto, S. Otani, F. Kitahata, M. Murakawa, Y. Itsui, M. Nakagawa, S. Azuma, M. Watanabe
Journal: Journal of Hepatology (2016)
Prospective, randomized trial comparing harmonic scalpel and electrocautery in breast surgery.
Authors: Tsuyoshi Mori, Hajime Abe, Yuki Kawai, Koichiro Murakami, Hiroya Akabori, Tsuyoshi Yamaguchi, Hiromichi Sonoda, Tomoharu Shimizu, Hisanori Shiomi, Yoshihiro Kubota, Shigeyuki Naka, Satoshi Murata, Hiroshi Yamamoto, Tomoko Umeda, Tohru Tani
Journal: Journal of Clinical Oncology (2013)

e12014 Background: The objective of this study was to compare the potential advantages of the harmonic scalpel with those of electrocautery for axillary lymph node dissection in breast surgery. Methods: A prospective randomized study of axillary lymph node dissection procedures performed between March 2011 and September 2012 was conducted. Primary breast cancer patients with axillary node-positive status (n = 25) were randomly assigned to the harmonic scalpel (group A, n = 13) or electrocautery (group B, n = 12) groups.The patients underwent breast-conservation surgery or mastectomy with a level I and II axillary dissection, which was performed by one surgeon. The time required for resection and the blood loss during the lymphadenectomy were recorded. The HARMONIC FOCUS (Ethicon Endo-Surgery, Inc.) was used as the ultrasonic scalpel. A low-pressure vacuum drain was placed in the axilla and removed when the drainage volume reduced to less than 50 ml over 24 hours. After the operations, the patients were assessed for the presence of seroma in an outpatient setting. Results: Resection timein group A was significantly shorter than that in group B (mean, 28.6 ± 5.1 vs. 40.3 ± 5.6 min; P = 0.0001). Similarly, blood loss in group A was significantly lower than that in group B (mean, 7.9 ± 5.3 vs. 22.9 ± 11.5 ml; P = 0.001). Duration of drain placement in group A was significantly lower than that in group B (mean, 3.5 ± 1.1 vs. 5.0 ± 0.9 days; P = 0.01), and the seroma rate in group A was lower than that in group B (23% vs. 66%; P = 0.04). Conclusions: For axillary lymph node dissection, the harmonic scalpel is more effective in terms of resection time, blood loss, duration of drain placement, and postoperative seroma formation.
The Levels of Monoamine Neurotransmitters in HCV Patients Treated with Ledipasvir (Ldv)/Sofosbuvir (Sof)
Authors: P. Golabi, E. Elsheikh, A. Karrar, J.M. Estep, I. Younossi, M. Stepanova, L. Gerber, Z.M. Younossi
Journal: Journal of Hepatology (2016)
Prospective Study of Oral Valganciclovir for Pre-Emptive Therapy of Cytomegalovirus After Allogeneic Stem Cell Transplantation.
Authors: Rafael De La Camara, Lourdes Vazquez, Javier Lopez, Carlos Solano, David Serrano, Ana Gracia-Noblejas, Josep-Maria Ribera, Christelle Ferra
Journal: Blood (2009)
Hepatitis B Virus Precore-, Basal Core Promotor- and Pres-Gene Variants: Importance for Reactivation in a Large Cohort of HBS Antigen Carriers
Authors: L. Sommer, K.-H. Peiffer, J. Vermehren, V. Knop, C. Sarrazin, S. Zeuzem
Journal: Journal of Hepatology (2016)
High incidence and persistence of airborne allergen sensitization up to age 19 years
Authors: E. Rönmark, K. Warm, A. Bjerg, H. Backman, L. Hedman, B. Lundbäck
Journal: Allergy (2016)

Longitudinal population-based studies about the natural history of allergic sensitization are rare. The aim was to study incidence and persistence of airborne allergen sensitization up to young adulthood and risk factors for early and late onset of sensitization.All children aged 7-8 years in two municipalities in Northern Sweden were invited to a parental questionnaire and skin prick tests (SPTs) to ten airborne allergens, and 2148 (88%) participated. The protocol was repeated at age 11-12 and 19 years, and 1516 participated in all three examinations.Prevalence of any positive SPT increased from 20.6% at age 7-8 years to 30.6% at 11-12 years, and 42.1% at 19 years. Animals were the primary sensitizers at age 7-8 years, 16.3%, followed by pollen, 12.4%. Mite and mold sensitization was low. Mean annual incidence of any positive SPT varied between 2.8 and 3.4/100 per year, decreased by age for animal, and was stable for pollen. Sensitization before age 7-8 years was independently associated with family history of allergy, OR 2.1 (95% CI 1.6-2.8), urban living, OR 1.9 (95% CI 1.2-2.9), and male sex, OR 1.3 (95% CI 1.0-1.7), and negatively associated with birth order, OR 0.8 (95% CI 0.7-1.0), and furry animals at home, OR 0.7 (95% CI 0.7-0.9). Incidence after age 11-12 years was associated only with family history of allergy. Multisensitization at age 19 years was significantly associated with early age at sensitization. Remission of sensitization was uncommon.The increasing prevalence of allergic sensitization by age was explained by high incidence and persistence. After age 11-12 years, the factors urban living, number of siblings, and male sex lost their importance.
The relation between the location and size of myocardial infarction and their reciprocal influences on post-infarction left ventricular remodeling
Authors: PG Masci, Javier Ganame, M Francone, Walter Desmet, Lorenzoni, M Mangia, A Barison, I Carbone, M Lombardi, L Agati, Stefan Janssens, Jan Bogaert
Journal: Journal of the American College of Cardiology (2011)
Efficacyand Safety of Ombitasvir/Paritaprevir/Ritonavir, with or without Ribavirin, in Patients with HCV Genotype 4 Infection — Real-World Experience from Qatar
Authors: M.F. Derbala, A.M. Amer, S. Alkaabi, O. Aljyli, Y. Kamel, K. Sultan, E.A. Elsayad, A. Amin, F.I. Pasic, M. Elshaikh, M. Elshaikh
Journal: Journal of Hepatology (2016)
Breast density and calculated breast cancer risk.
Authors: F. B. Khan, F. Kingsley, K. Dittus, B. L. Sussman, M. E. Wood
Journal: Journal of Clinical Oncology (2010)

1556 Background: Breast density is an independent risk factor for breast cancer; associated with an OR ≥ 4 for very dense breast tissue. Given the prevalence of breast density, the attributable risk may be as high as 33%. The majority of density is determined by heredity however, many factors influence density. Several techniques to quantify density have been described. Here, we evaluate density using the visual analog scale and correlate density with calculated breast cancer risk in a population of women at increased risk for breast cancer. Methods: The High Risk Breast Program database, for women with strong family history, BRCA mutations, high risk pathology or prior chemoradiotherapy for lymphoma, was initiated in 2003 and contains 450+ women. A subset of 37 women ranging in age from 28-63 with a mean lifetime Gail Risk of 22% is the subject of this analysis. Data collected included: mammograms, a medical and dietary history, and BMI. Breast density was interpreted (at baseline and 2 years) from mammograms using a visual analogue scale and reliability was evaluated. Multivariate analyses were performed, using Pearson correlations. Results: Intra-rater variability for density determination at 0 (r = 0.866) and 2 (r = 0.912) year time points was comparable to published studies. Of the variables analyzed, BMI and weight had the most significant influence upon density, with an inversely proportional relationship at both time points (each p = 0.001). Percent density had a significant inversely proportional relationship to short-term (5 year) Gail Risk at both 0 (r = -0.396; p = 0.034) and 2 year (r = -0.359; p = 0.043) time points. Conclusions: Our early results demonstrate the reliability of the visual analogue scale (with high intra-rater variability and correlation with known influences). The negative correlation with risk (also noted by Cuzick et. al 2009) bears further exploration. Breast density may not be an important predictor of risk in high-risk populations. Study accrual is ongoing, and further analysis will clarify this trend. Future studies will need to evaluate the influence of breast density in high and average risk populations. No significant financial relationships to disclose.
On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1–6 HCV Infection Treated with Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the Astral-1, Astral-2, and Astral-3 Studies
Authors: S. Alqatani, S. Zeuzem, S. Bourgeois, P. Mathurin, S. Rojter, G. Everson, A. Abergel, V. De Ledinghen, L. Liu, X. Ding, J. Mcnally, A. Osinusi, D. Brainard, M. Subramanian, A. Mangia, M. Sulkowski
Journal: Journal of Hepatology (2016)
An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection
Authors: Abraham Shaked, Bao‐Li Chang, Michael R. Barnes, Peter Sayre, Yun R. Li, Smita Asare, Michele DesMarais, Michael V. Holmes, Toumy Guettouche, Brendan J. Keating
Journal: Hepatology (2016)

The ability to noninvasively diagnose acute cellular rejection (ACR) with high specificity and sensitivity would significantly advance personalized liver transplant recipient care and management of immunosuppression. We performed microRNA (miRNA) profiling in 318 serum samples from 69 liver transplant recipients enrolled in the Immune Tolerance Network immunosuppression withdrawal (ITN030ST) and Clinical Trials in Organ Transplantation (CTOT-03) studies. We quantified serum miRNA at clinically indicated and/or protocol biopsy events (n = 130). The trajectory of ACR diagnostic miRNAs during immunosuppression withdrawal were also evaluated in sera taken at predetermined intervals during immunosuppression minimization before and at clinically indicated liver biopsy (n = 119). Levels of 31 miRNAs were significantly associated with ACR diagnosis with two miRNAs differentiating ACR from non-ACR (area under the receiver operating characteristic curve = 90%, 95% confidence interval = 82%-96%) and predicted ACR events up to 40 days before biopsy-proven rejection. The most differentially expressed miRNAs were low or absent in the blood of healthy individuals but highly expressed in liver tissue, indicating an ectopic origin from the liver allograft. Pathway analyses of rejection-associated miRNAs and their target messenger RNAs (mRNAs) showed induction of proinflammatory and cell death-related pathways. Integration of differentially expressed serum miRNA with concordant liver biopsy mRNA demonstrates interaction between molecules with a known role in transplant rejection. Conclusion: Distinct miRNA levels profiled from sera at the time of clinical allograft dysfunction can be used to noninvasively diagnose ACR. Predictive trajectories of the same profile during supervised immunosuppression minimization diagnosed rejection up to 40 days prior to clinical expression. The rejection-associated miRNAs in sera appear to be ectopically expressed liver and specific immune cell miRNAs that are biologically related, and the consequences of immune-mediated damage to the allograft. (Hepatology 2017;65:269-280).
The DOC combination in advanced gastric cancer: Preliminary data of a phase II study.
Authors: A. Pancotti, A. Santomaggio, G. Cianci, T. Scipioni, F. Martella, R. Foglia, P. Marchetti
Journal: Journal of Clinical Oncology (2011)

104 Background: We describe activity of first line chemotherapy in advanced gastric carcinoma with docetaxel (DTX), oxaliplatin (OHP) and capecitabine (CAP). Methods: Patients (pts) were enrolled in the phase II study, if they had the main subsequent criteria: histologically confirmed diagnosis of advanced gastric cancer (AGC) (local advanced or metastatic disease); normal renal and hepatic function; no myocardial infarction or angina pectoris; no uncontrolled severe diseases or active infections. Treatment schedule: DTX at fixed dose of 65 mg/m 2 on day 1, OHP at fixed dose of 110 mg/m 2 on day 1, CAP at fixed dose of 1,600 mg/ m 2 with crhonomodulation in trhee daily administration from day 1 to day 14, every 3 weeks. Dose-limiting toxicity (DLT): G3 non-haematological or G4 haematological. Study design: Simon two-stage phase II optimal design with power (1- b) 80%, error a 5%, error b 20%, P 0 40%, P 1 60%. Planned sample size: I stage 7/16, II stage 23/46. Primary endpoint was response rate (RR). Secondary endpoints were time to progression (TTP), overall survival (OS), toxicity and quality of life. Results: 38 pts were enrolled: 24 men and 14 women, median age of 58 years (range 50-67). Median number of cycles per pts was 4,5 (range 3-6). Total cycles administered: 41. Cumulative G3-4 toxicities were: neutropenia 21%, anemia 14%, asthenia 9%. G1-2 toxicities were: diarrhea 22%, neurotoxicity 18%. Median received-DI of DTX: 20 mg/mq/week (93% of recommended-DI), OHP 35 mg/mq/week (95%), CAP 7,000 mg/mq/week (94%) per patient, respectively. Overall pts were assessable (according to intent-to-treat analysis) with 58% (a0.05, CI + 29) of objective responses (OR): 7 partial responses, 4 stable disease and 1 progression. The disease control rate (DCR) was 91%. TTP and OS not done because median follow-up was of 8 months (2-15) only. Conclusions: The combination DOC is tolerable without G3-4 toxicity and preliminary data show very high activity. No significant financial relationships to disclose.
TG-2349, a Potent Protease Inhibitor, Plus Pegifn/RBV Provides Excellent Virological Responses for Harder-To-Treat Subpopulations of HCV-1B Non-Cirrhotic Patients
Authors: M.-L. Yu, S.-J. Hsu, C.-T. Yeh, C.-H. Hung, M.-Y. Chen, P.-J. Chen, Y.- H. Huang, P.-N. Cheng, C.-M. Chen, L.-W. Chang, C.-C. Lin, F. Sheen, C.-H.R. King, E. Kuo, M.-C. Hsu
Journal: Journal of Hepatology (2016)
<i>Portrait of Virginia</i>
Authors: Thomas B. Cole
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Prognostic Factors and Outcomes of Essential Thrombocythemia When Transformed to Myelodysplastic Syndrome and Acute Myeloid Leukemia
Authors: Yaman Suleiman, Samir Dalia, Jijun Liu, Jeremy W Bowers, Eric Padron, Jeffrey E Lancet, Lynn C. Moscinski, Rami S Komrokji, Kenneth S. Zuckerman, Ling Zhang
Journal: Blood (2014)
Exercise-induced bronchoconstriction update—2016
Authors: John M. Weiler, John D. Brannan, Christopher C. Randolph, Teal S. Hallstrand, Jonathan Parsons, William Silvers, William Storms, Joanna Zeiger, David I. Bernstein, Joann Blessing-Moore, Matthew Greenhawt, David Khan, David Lang, Richard A. Nicklas, John Oppenheimer, Jay M. Portnoy, Diane E. Schuller, Stephen A. Tilles, Dana Wallace
Journal: Journal of Allergy and Clinical Immunology (2016)
ANG2/ANG1 Ratio as Non-Invasive Biomarker of Cirrhosis in Patients with Chronic Hepatitis C
Authors: Á.H. Bartolomé, R. López-Rodriguez, M.J. Borque, Y. Rodriguez-Muñoz, L. García-Buey, R. Moreno-Otero, P. Sanz-Cameno
Journal: Journal of Hepatology (2016)
P0493 : Selectin-targeting nanoparticles for immunomodulatory therapy of liver diseases
Authors: M. Bartneck, C.T. Schlößer, K.T. Warzecha, T. Lammers, C. Trautwein, K. Moog, H. Kunz, R. Zentel, M. Barz, F. Tacke
Journal: Journal of Hepatology (2015)
Real-Life Results of Sofosbuvir Based Therapy for Egyptian Patients with Hepatitis C and Advanced Fibrosis-Cirrhosis
Authors: W. Doss, G. Esmat, M. El-Serafy, W. El-Akel, A. Yosry, M. El-Sayed, M. Hassany, M. El-Kassas, K. Kabil, I. Waked
Journal: Journal of Hepatology (2016)
Clinical Utility of Hepatitis B Core-Related Antigen (HBcrAg) in the Treatment of Hepatitis Delta
Authors: B. Maasoumy, M. Wöbse, S. Hardtke, P. Lehmann, B. Bremer, B. Heidrich, M. Cornberg, C. Yurdaydin, M.P. Manns, H. Wedemeyer
Journal: Journal of Hepatology (2016)